

Memphasys' \$1,200,000 Capital Raise Strongly Supported as Investors Back Felix™

Placement Completed & Peters Investments Convertible Note Extended 12 Months

Highlights

- Firm commitments received to raise \$1.2M through a share placement at an issue price of \$0.005
- The Placement was strongly supported by new and existing investors
- Proceeds will be used to support Felix™ commercial execution, including expansion of the direct selling model and manufacturing cartridges to meet growing customer demand
- Peters Investments Convertible Note extended to June 20, 2027

Memphasys Limited (ASX: MEM) (“Memphasys” or “the Company”) is pleased to announce that it has secured firm commitments from sophisticated and professional investors to raise \$1.2M (before costs) at an issue price of \$0.005 per share (the “Placement”). The Placement was strongly supported by both new and existing sophisticated and professional investors.

The Placement follows a period of strong commercial activity and momentum for the Company, including the recently announced (June 16th 2026), 12-month exclusive national supply agreement with Monash IVF Group Limited for the Felix™ system in Australia. Felix™ commercial contracts are now in place across Australia, Europe, the Middle East and North Africa, India, Japan and South East Asia.

Over the past six months, Memphasys has secured more than A\$2.5 million in minimum multi-year contracted revenues across five distribution partnerships, including a five-year supply agreement with CFA Italia providing access to mainland Europe (minimum contract value ~A\$925,000)¹, an exclusive multi-year agreement with ITL across the Middle East and North Africa covering approximately 353 clinics in 15 countries, a direct supply partnership with Andrology Center/Andro Diagnostics reaching more than 200 IVF clinics across India², a supply agreement with a Vietnamese distributor valued at A\$530,000³, and continued traction in Japan through Nishitan ART Clinic Group⁴. The Monash IVF agreement, executed on 16 June 2026, represents the Company’s largest annual commercial agreement to date and its first in the Australian market⁵.

Proceeds from the Placement will be applied towards advancing Felix™ commercialisation execution, predominantly supporting manufacturing inventory build to meet growing contracted and anticipated demand and scaling direct selling engagement activities across the globe.

¹ Refer ASX announcement dated 22 December 2025

² Refer ASX announcement dated 8 September 2025, 2 February 2026 and 27 May 2026

³ Refer ASX announcement dated 1 June 2026

⁴ Refer ASX announcement dated 24 October 2025

⁵ Refer ASX announcement dated 16 June 2026

Placement Details

The Placement comprises the issue of a total of 240,000,000 fully paid ordinary shares at an issue price of \$0.005 per share, raising \$1.2M (before costs) to sophisticated and professional investors. The 240,000,000 placement shares will be issued under the Memphasys' existing ASX Listing Rule 7.1 placement capacity.

The issue price of \$0.005 is equal to the last closing price and the 5-day and 15-day VWAP.

The new shares will rank equally with existing Memphasys fully paid ordinary shares quoted on the ASX.

Settlement of the placement is expected to occur on Wednesday, 24 June 2026, with the Shares to be allotted on or around Thursday, 25 June 2026.

Lynx Advisors Pty Ltd acted as Lead Manager to the Placement and are entitled to a fee of 6% on the funds raised and 2,500,000 Options with an exercise price of \$0.007 per option expiring 31 December 2027 ("Lead Manager Options") subject to shareholder approval at an upcoming EGM.

"I am very pleased to see the strong support for this capital raise from both new and existing shareholders," said Mr David Tasker, Chair of Memphasys.

The recent execution of the exclusive 12-month national Supply Agreement with Monash IVF Group for the Felix™ System, as announced on 16 June 2026, represents a significant commercial milestone for Memphasys. With this capital raising the Company is well positioned to continue its transition from initial commercial validation to scaled execution."

Peters Investments Convertible Note Extended 12 Months

The Company also advises that it has executed an amendment deed with Peters Investments Pty Ltd, a major long-term shareholder, to extend the repayment terms of its existing Convertible Note agreements.

Under the amendment, the maturity date of the convertible notes has been extended by 12 months to 30 June 2027, providing the Company with additional time and flexibility to execute on its rapidly expanding commercialisation strategy. All other terms of the convertible note, including the interest rate, conversion rights, and conversion price, remain unchanged. The amendments do not alter the principal amount outstanding under the notes, nor do they change the existing conversion terms.

The Board considers the extension of the repayment terms to be a key component of the Company's focused execution strategy, strengthening balance sheet flexibility while Memphasys continues to progress its commercial and regulatory objectives. Peters Investments has been a shareholder of the Company for many years, and the Board views this amendment as a strong signal of the continued confidence in both the Company and the strategic direction being implemented by the Board.

All other terms and conditions of the convertible not agreements remain unchanged.

Mr Tasker added:

"The 12-month extension of the convertible note on the same terms provides the balance sheet stability the Company needs to execute on its rapidly expanding commercialisation strategy. With A\$2.5 million in minimum contracted revenues secured across five international partnerships, and Monash IVF now on board as our anchor Australian customer, the Company is advancing into a period of scaled commercial

execution. The Board is appreciative of the continued support from Peters Investments, whose long-standing confidence in Memphasys is a strong endorsement of the direction we are taking.”

Authorised by the Board of Memphasys Limited.

Ends

For further information, please contact:

Colin Jacoby

Chapter One Advisors

T: +61 433 112 936

E: cjacoby@chapteroneadvisors.com.au

About Memphasys

Memphasys Limited (ASX: MEM) is an Australian-based reproductive biotechnology company commercialising the Felix™ System, a patented bio separation technology that isolates the most viable sperm cells for human assisted reproduction.

By combining electrophoresis and size-exclusion membranes, Felix™ delivers a fast, gentle and standardised sperm selection process that enhances sperm quality and reduces laboratory time. The system replaces traditional centrifugation, which can cause cellular stress and DNA damage, offering clinicians a superior, repeatable alternative.

Memphasys' commercial strategy focuses on building contracted sales through direct and distribution-led channels, scaling production to improve margins, and establishing Felix™ as a new global standard in sperm preparation for ART procedures.

Website: www.memphasys.com

The Felix™ System is a registered trademark of Memphasys Limited. All rights reserved.